Sky Sports has partnered with the England and Wales Cricket Board (ECB) to target 100 communities with grassroots cricket initiative and have launched Dynamos Cricket Intros.
It is a new multi-year initiative that will champion inclusion, and encourage more children to take up the game of cricket regardless of gender, ability, or background.
With the ambition of reaching children who might not ordinarily have access to cricket for a variety of reasons, the three-year investment will enable schools and community centres in underprivileged areas to provide courses for free.
Launching on June 1, Dynamos Cricket Intros is designed to tackle existing barriers and inspire the next generation to pick up a bat and ball, particularly in urban areas, by introducing children to a simplified and more dynamic game of countdown cricket. It will also start a free introductory initiative targeting 100 towns and cities across the UK.
With a focus on accessibility and encouragement ahead of The Hundred competition this summer, the investment in the initiative is broken down into three main parts; recruitment and training, access to free courses and the creation of fun educational videos delivered by stars of the game.
The Dynamos Cricket Intros scheme will offer training to 300 new coaches, which will include coaching experience and mentoring support with all kit and equipment provided for free. Once trained, they will span 150 schools and 150 community centres across the UK. Applications to take part in this new coach training scheme are open to people of all backgrounds from today (27) via The Hundred Rising.
Finally, a series of fun and educational videos featuring England star Jofra Archer and Tammy Beaumont will be made available to all via the Sky Sports YouTube channel. The participation collection will introduce cricket to teachers, parents and children.
Nick Pryde, director of Participation and Growth at the ECB said: “We are continuously grateful for the depth and breadth of our Sky Sports partnership. Their generous investment into creating Dynamos Cricket Intros is an incredible example of their dedication to growing the number of children playing cricket in this country and to making the game more inclusive and diverse. As we launch The Hundred this year, we are excited to join forces with Sky on this project to help break down barriers to entry and inspire cricket’s future generations. In addition to Dynamos Cricket Intros, the ECB is also helping existing clubs open up to newcomers during the summer holidays by providing funding to up to 2,000 clubs.”
Rob Webster, managing director of Sky Sports said: “At Sky Sports we believe all children should have the opportunity to play cricket regardless of gender, ability or background. As a long-standing partner of the ECB we have invested in Dynamos Cricket Intros to tackle head-on some of the biggest barriers to participation. We can’t wait to work in 100 communities across the UK this summer inspiring more and more children to start playing the game that has been at the heart of Sky Sports for decades.”
The Hundred is a new 100-ball cricket competition created by the ECB and set to kick off on July 21.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.